Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

パーキンソン病治療薬の世界市場予測(~2022年):カルビドパ/レボドパ、ドパミン受容体刺激薬、MAO阻害薬

◆タイトル:Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
◆商品コード:PH-5674
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年10月24日
◆ページ数:115
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥632,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥744,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥912,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、パーキンソン病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、薬種類別分析、流通チャネル別分析、地域別分析、パーキンソン病治療薬の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Parkinson’s disease treatment market projected to grow at a CAGR of 6.1%”The Parkinson’s disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022 to grow at a CAGR of 6.1%. Factors such as the increasing aging population worldwide and government funding for research on Parkinson’s disease are driving this market. However, the availability of alternative treatments is expected to restrain this market.
“The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period”
On the basis of drug class, the Parkinson’s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by its potency and wide adoption in the treatment of Parkinson’s disease.
“The online pharmacies segment to grow at the fastest rate during the forecast period”
By distribution channel type, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register highest CAGR during the forecast period. Advantages such as 24/7 ordering, home delivery, and discounts on medicines are the driving factors for this segment.
“Europe to hold the largest share of the regional market during the forecast period”
Geographically, the Parkinson’s disease treatment market is dominated by Europe, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to command the largest share of the Parkinson’s disease treatment market. The large share of this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. The Asian region is estimated to grow at the fastest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1 – 70% and Tier 2 – 30%
• By Designation – C-level – 62%, Director Level – 21%, Others – 17%
• By Region – North America – 50%, Europe – 20%, Asia – 30%

Key players operating in the Parkinson’s disease treatment market include Teva(Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).
Research Coverage:
The report analyses the Parkinson’s disease treatment market by drug class, distribution channel, patient care setting, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report analyses developments and strategies adopted by key players to maintain and increase their shares in the market. The above-mentioned market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.

The report provides insights on the following strategies:

• Market Penetration: The report analyzes the Parkinson’s disease treatment market by drug class, distribution channel, and patient care setting
• Competitive Assessment: In-depth assessment of the market strategies and geographic and business segments of the leading players in the Parkinson’s disease treatment market
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various drug classes across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the Parkinson’s disease treatment market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.2.1 MARKETS COVERED 13
1.2.2 YEARS CONSIDERED FOR THE STUDY 13
1.3 CURRENCY 14
1.4 LIMITATIONS 14
1.5 STAKEHOLDERS 14

2 RESEARCH METHODOLOGY 15
2.1 RESEARCH DATA 16
2.1.1 SECONDARY DATA 16
2.1.1.1 Key data from secondary sources 16
2.1.2 PRIMARY DATA 17
2.1.2.1 Key data from primary sources 18
2.2 MARKET SIZE ESTIMATION 18
2.2.1 BOTTOM-UP APPROACH 19
2.2.2 TOP-DOWN APPROACH 20
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.4 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23

4 PREMIUM INSIGHTS 27
4.1 PARKINSON’S DISEASE TREATMENT MARKET OVERVIEW 27
4.2 GEOGRAPHIC ANALYSIS: PARKINSON’S DISEASE TREATMENT MARKET,
BY DRUG CLASS 28
4.3 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET,
BY COUNTRY 29
4.4 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET 30

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 31
5.2 MARKET DYNAMICS 31
5.2.1 DRIVERS 32
5.2.1.1 Growth in aging population and the associated increase in the prevalence of Parkinson’s disease 32
5.2.1.2 Government funding for research 32

5.2.2 RESTRAINTS 33
5.2.2.1 Availability of alternative treatments 33
5.2.3 OPPORTUNITIES 34
5.2.3.1 Patent expiry of branded drugs 34
5.2.3.2 Strong drug pipeline 34

6 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS 36
6.1 INTRODUCTION 37
6.2 CARBIDOPA/LEVODOPA 37
6.3 DOPAMINE RECEPTOR AGONISTS 39
6.4 MAO INHIBITORS 40
6.5 COMT INHIBITORS 42
6.6 ANTICHOLINERGICS 43
6.7 OTHER DRUGS 45

7 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 47
7.1 INTRODUCTION 48
7.2 HOSPITAL PHARMACIES 49
7.3 RETAILER PHARMACIES 50
7.4 ONLINE PHARMACIES 51

8 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING 52
8.1 INTRODUCTION 53
8.2 HOSPITALS 54
8.3 CLINICS 55

9 PARKINSON’S DISEASE TREATMENT MARKET, BY REGION 57
9.1 INTRODUCTION 58
9.2 EUROPE 59
9.3 NORTH AMERICA 61
9.3.1 U.S. 63
9.3.2 CANADA 65
9.4 ASIA 67
9.4.1 JAPAN 69
9.4.2 CHINA 71
9.4.3 REST OF ASIA 73
9.5 REST OF THE WORLD 75

10 COMPANY PROFILES 77
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
10.1 GSK 77
10.2 MERCK 79
10.3 NOVARTIS 81
10.4 TEVA 83
10.5 BOEHRINGER INGELHEIM 86
10.6 IMPAX 88
10.7 ABBVIE 90
10.8 VALEANT PHARMACEUTICALS 92
10.9 LUNDBECK 94
10.10 SUN PHARMA 96
10.11 WOCKHARDT 98
10.12 ACADIA 100
10.13 UCB 102

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

11 APPENDIX 105
11.1 INSIGHTS OF INDUSTRY EXPERTS 105
11.2 DISCUSSION GUIDE 106
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 110
11.5 AVAILABLE CUSTOMIZATIONS 111
11.6 RELATED REPORTS 112
11.7 AUTHOR DETAILS 113

LIST OF TABLES

TABLE 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SUMMARY 23
TABLE 2 AGEING POPULATION, BY REGION, 2015 VS 2030 32
TABLE 3 PARKINSON’S DISEASE TREATMENT MARKET: LIST OF PIPELINE DRUGS 34
TABLE 4 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2016–2022 (USD MILLION) 37
TABLE 5 CARBIDOPA/LEVODOPA MARKET, BY REGION, 2015–2022 (USD MILLION) 38
TABLE 6 NORTH AMERICA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 38
TABLE 7 ASIA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 38
TABLE 8 DOPAMINE RECEPTOR AGONISTS MARKET, BY REGION,
2015–2022 (USD MILLION) 39
TABLE 9 NORTH AMERICA: DOPAMINE RECEPTOR AGONISTS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 39
TABLE 10 ASIA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 40
TABLE 11 MAO INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION) 40
TABLE 12 NORTH AMERICA: MAO INHIBITORS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 41
TABLE 13 ASIA: MAO INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 41
TABLE 14 COMT INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION) 42
TABLE 15 NORTH AMERICA: COMT INHIBITORS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 42
TABLE 16 ASIA: COMT INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 43
TABLE 17 ANTICHOLINERGICS MARKET, BY REGION, 2015–2022 (USD MILLION) 43
TABLE 18 NORTH AMERICA: ANTICHOLINERGICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 44
TABLE 19 ASIA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 44
TABLE 20 OTHER DRUGS MARKET, BY REGION, 2015–2022 (USD MILLION) 45
TABLE 21 NORTH AMERICA: OTHER DRUGS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 45
TABLE 22 ASIA: OTHER DRUGS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 23 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL,
2015–2022 (USD MILLION) 48
TABLE 24 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES,
BY REGION, 2015–2022 (USD MILLION) 49
TABLE 25 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 26 PARKINSON’S DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES,
BY REGION, 2015–2022 (USD MILLION) 50
TABLE 27 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR RETAILER PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 28 PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES,
BY REGION, 2015–2022 (USD MILLION) 51
TABLE 29 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION) 51
TABLE 30 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING,
2015–2022 (USD MILLION) 53
TABLE 31 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION,
2015–2022 (USD MILLION) 54
TABLE 32 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION) 54
TABLE 33 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION) 55
TABLE 34 PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY REGION,
2015–2022 (USD MILLION) 55
TABLE 35 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS,
BY COUNTRY, 2015–2022 (USD MILLION) 56
TABLE 36 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015–2022 (USD MILLION) 56
TABLE 37 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION,
2015–2022 (USD MILLION) 58
TABLE 38 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 59
TABLE 39 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 60
TABLE 40 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 60
TABLE 41 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 62
TABLE 42 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY DRUG CLASS, 2015–2022 (USD MILLION) 62
TABLE 43 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 62
TABLE 44 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 63
TABLE 45 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 64
TABLE 46 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 64
TABLE 47 US: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 64
TABLE 48 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 65
TABLE 49 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 66
TABLE 50 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 66
TABLE 51 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 68
TABLE 52 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 68
TABLE 53 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 69
TABLE 54 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 69
TABLE 55 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 70
TABLE 56 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 70
TABLE 57 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 70
TABLE 58 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 71
TABLE 59 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 72
TABLE 60 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 72
TABLE 61 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 73
TABLE 62 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 74
TABLE 63 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 74
TABLE 64 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 75
TABLE 65 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 75
TABLE 66 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 76


LIST OF FIGURES

FIGURE 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET 13
FIGURE 2 RESEARCH DESIGN 15
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 17
FIGURE 4 PARKINSON’S DISEASE TREATMENT MARKET: BOTTOM-UP APPROACH 19
FIGURE 5 PARKINSON’S DISEASE TREATMENT MARKET: TOP-DOWN APPROACH 20
FIGURE 6 DATA TRIANGULATION METHODOLOGY 21
FIGURE 7 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2017 VS. 2022 24
FIGURE 8 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017 VS. 2022 24
FIGURE 9 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2017 VS. 2022 25
FIGURE 10 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION, 2017 VS. 2022 26
FIGURE 11 INCREASING PREVALENCE OF PARKINSON’S DISEASE TO DRIVE THE GROWTH OF THE PARKINSON’S DISEASE TREATMENT MARKET 27
FIGURE 12 CARBIDOPA/LEVODOPA SEGMENT AND JAPAN TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 28
FIGURE 13 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 29
FIGURE 14 EUROPE TO REGISTER THE HIGHEST MARKEST SHARE DURING THE FORECAST PERIOD 30
FIGURE 15 PARKINSON’S DISEASE TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 31
FIGURE 16 HOSPITAL PHARMACIES TO CONTINUE TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD 48
FIGURE 17 HOSPITALS SEGMENT TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD 53
FIGURE 18 PARKINSON’S DISEASE TREATMENT MARKET: GEOGRAPHIC SNAPSHOT
(2017-2022) 58
FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT 61
FIGURE 20 ASIA: MARKET SNAPSHOT 67
FIGURE 21 GSK .: COMPANY SNAPSHOT 77
FIGURE 22 MERCK: COMPANY SNAPSHOT 79
FIGURE 23 NOVARTIS: COMPANY SNAPSHOT 81
FIGURE 24 TEVA : COMPANY SNAPSHOT 83
FIGURE 25 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT 86
FIGURE 26 IMPAX: COMPANY SNAPSHOT 88
FIGURE 27 ABBVIE.: COMPANY SNAPSHOT 90
FIGURE 28 VALEANT: COMPANY SNAPSHOT 92
FIGURE 29 LUNDBECK: COMPANY SNAPSHOT 94
FIGURE 30 SUN PHARMA: COMPANY SNAPSHOT 96
FIGURE 31 WOCKHARDT: COMPANY SNAPSHOT 98
FIGURE 32 ACADIA.: COMPANY SNAPSHOT 100
FIGURE 33 UCB: COMPANY SNAPSHOT 102


【レポートのキーワード】

パーキンソン病治療薬、カルビドパ、レボドパ、ドパミン受容体刺激薬、モノアミン酸化酵素阻害薬

★調査レポート[パーキンソン病治療薬の世界市場予測(~2022年):カルビドパ/レボドパ、ドパミン受容体刺激薬、MAO阻害薬] ( Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022 / PH-5674) 販売に関する免責事項
[パーキンソン病治療薬の世界市場予測(~2022年):カルビドパ/レボドパ、ドパミン受容体刺激薬、MAO阻害薬] ( Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022 / PH-5674) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆